134 related articles for article (PubMed ID: 22108336)
1. A liquid phase based C. elegans behavioral analysis system identifies motor activity loss in a nematode Parkinson's disease model.
Zheng M; Gorelenkova O; Yang J; Feng Z
J Neurosci Methods; 2012 Mar; 204(2):234-7. PubMed ID: 22108336
[TBL] [Abstract][Full Text] [Related]
2. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.
Calahorro F; Ruiz-Rubio M
Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of LRRK2-associated Parkinson's disease in central Norway.
Aasly JO; Toft M; Fernandez-Mata I; Kachergus J; Hulihan M; White LR; Farrer M
Ann Neurol; 2005 May; 57(5):762-5. PubMed ID: 15852371
[TBL] [Abstract][Full Text] [Related]
4. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.
Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG
Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Liu Z; Hamamichi S; Lee BD; Yang D; Ray A; Caldwell GA; Caldwell KA; Dawson TM; Smith WW; Dawson VL
Hum Mol Genet; 2011 Oct; 20(20):3933-42. PubMed ID: 21768216
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
7. Regulation of physiologic actions of LRRK2: focus on autophagy.
Ferree A; Guillily M; Li H; Smith K; Takashima A; Squillace R; Weigele M; Collins JJ; Wolozin B
Neurodegener Dis; 2012; 10(1-4):238-41. PubMed ID: 22204929
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
Lee BD; Dawson VL; Dawson TM
Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
[TBL] [Abstract][Full Text] [Related]
9. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
10. The Functional Assessment of LRRK2 in Caenorhabditis elegans Mechanosensory Neurons.
Kuwahara T
Methods Mol Biol; 2021; 2322():175-184. PubMed ID: 34043203
[TBL] [Abstract][Full Text] [Related]
11. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.
Squillaro T; Cambi F; Ciacci G; Rossi S; Ulivelli M; Malandrini A; Mencarelli MA; Mari F; Renieri A; Ariani F
J Hum Genet; 2007; 52(3):201-204. PubMed ID: 17235449
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.
Saha S; Guillily MD; Ferree A; Lanceta J; Chan D; Ghosh J; Hsu CH; Segal L; Raghavan K; Matsumoto K; Hisamoto N; Kuwahara T; Iwatsubo T; Moore L; Goldstein L; Cookson M; Wolozin B
J Neurosci; 2009 Jul; 29(29):9210-8. PubMed ID: 19625511
[TBL] [Abstract][Full Text] [Related]
13. Modelling the functional genomics of Parkinson's disease in Caenorhabditis elegans: LRRK2 and beyond.
Chandler RJ; Cogo S; Lewis PA; Kevei E
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34397087
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans.
Yuan Y; Cao P; Smith MA; Kramp K; Huang Y; Hisamoto N; Matsumoto K; Hatzoglou M; Jin H; Feng Z
PLoS One; 2011; 6(8):e22354. PubMed ID: 21857923
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
16. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
17. Investigating convergent actions of genes linked to familial Parkinson's disease.
Wolozin B; Saha S; Guillily M; Ferree A; Riley M
Neurodegener Dis; 2008; 5(3-4):182-5. PubMed ID: 18322385
[TBL] [Abstract][Full Text] [Related]
18. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 as a therapeutic target in Parkinson's disease.
Tan EK; Schapira AH
Eur J Neurol; 2011 Apr; 18(4):545-6. PubMed ID: 21199179
[No Abstract] [Full Text] [Related]
20. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Li Y; Liu W; Oo TF; Wang L; Tang Y; Jackson-Lewis V; Zhou C; Geghman K; Bogdanov M; Przedborski S; Beal MF; Burke RE; Li C
Nat Neurosci; 2009 Jul; 12(7):826-8. PubMed ID: 19503083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
